Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS EBITDA Margin

EBITDA as a percentage of revenue.

Novartis AGNYSE: NVS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin holds steady near 41.2%

EBITDA Margin was 41.2% in Q2 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 40.0%, down 1.1 pp year over year. Over 3 fiscal years it widened by 8.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 42.8% for the fiscal year ending Dec 2026, up from 41.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
41.2%+1.2 pp QoQ
Last fiscal yearDec 2025
41.9%+1.9 pp YoY
LTMJun 2026
40.0%-1.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.2 pp+19.0 pp+18.8 pp
1 year+1.9 pp+0.9 pp-1.0 pp
3 years+8.2 pp+1.2 pp-7.0 pp
5 years+3.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
41.9%
Year-over-year change
+1.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NVS compares with its peers on the latest reported figures

  • NVS's LTM Jun 2026 EBITDA Margin of 40.0% is the 2nd highest of the 11 companies compared; the peer median is 30.6%.
  • Its year-over-year change of -1.1 pp is the 7th highest of 11, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +8.2 pp compares with a peer median of +4.9 pp.
NVS Competitors Peer median
EBITDA Margin for NVS and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202654.9% -0.5 pp+7.3 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding NVS) 30.6%-0.6 pp+4.9 pp

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.97B43.46B46.66B51.72B54.81B
Cost of Revenue11.74B11.58B12.47B12.83B13.69B
Gross Profit32.24B31.88B34.19B38.9B41.12B
Gross Margin73.3%73.4%73.3%75.2%75.0%
Research & Development8.64B9.17B11.37B10.02B10.74B
Selling, General & Admin12.83B12.19B12.52B12.57B13.31B
Operating Expenses22.18B23.93B24.42B24.35B24.05B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
EBITDA30.91B14.68B18.26B20.72B22.99B
EBITDA Margin70.3%33.8%39.1%40.1%41.9%
Operating Income10.06B7.95B9.77B14.54B17.07B
Operating Margin22.9%18.3%20.9%28.1%31.2%
Interest Income71M377.74M629.24M567.68M374.91M
Interest Expense905M834.62M876.12M1.04B1.19B
Other Income / Expenses14.47B(769M)(646M)(904M)(638.25M)
Income Before Tax24.53B7.18B9.12B13.64B16.44B
Pre-Tax Margin55.8%16.5%19.6%26.4%30.0%
Income Tax Expense1.63B1.13B551M1.7B2.4B
Net Income24.02B6.96B14.85B11.94B14.06B
Net Margin54.6%16.0%31.8%23.1%25.6%
EPS (Basic)10.713.197.155.927.25
EPS (Diluted)10.633.177.105.877.19
Weighted Avg Shares2.24B2.18B2.08B2.02B1.94B
Weighted Avg Shares (Diluted)2.26B2.2B2.09B2.04B1.96B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.